17-Nov-2026 14:58:35
SUN PHARMA ,NTPC ; Buy flows on DII desk , Large prominent insurance company buyer in trade - NDTV PROFIT 🟢🟢
SUN PHARMA ,NTPC ; Buy flows on DII desk , Large prominent insurance company buyer in trade - NDTV PROFIT 🟢🟢
Latest market headlines for SUNPHARMA on Terminal.
17-Nov-2026 14:58:35
SUN PHARMA ,NTPC ; Buy flows on DII desk , Large prominent insurance company buyer in trade - NDTV PROFIT 🟢🟢
04-Nov-2026 13:07:40
Sun Pharma files application to allow manufacture and launch of generic oral semaglutide Alert: Sun Pharma was to seek permission of court before launch of the…
04-Nov-2026 10:04:52
• Clarification filed after BSE and NSE sought comments on a 30 October 2026 report on India ordering a halt to eye-care drug production at the Assam plant aft…
02-Nov-2026 20:59:40
• Company says the news report on halting eye-care drug production at its Assam plant relates to developments from August 2026 • Matter was assessed at the rel…
02-Nov-2026 08:28:07
• Global innovative medicine sales UP 6.9% YoY at $356 Mn, impacted by slower US Ilumya sales. • US FDA approves Ilumya for psoriatic arthritis, expanding its…
02-Nov-2026 08:07:21
• US Ilumya execution challenges may take a few quarters to resolve; psoriatic arthritis launch planned in November. • Organon acquisition expected to close in…
01-Nov-2026 10:37:53
SUN PHARMA Q2 FY27 CONCALL: MAINTAINS HIGH SINGLE-DIGIT FY27 REVENUE GROWTH GUIDANCE; ORGANON ACQUISITION TARGETED FOR Q4 FY27, R&D SPENDING TO ACCELERATE IN H…
30-Oct-2026 14:22:02
SUN PHARMA Q2 : U.S SALES AT $ 356 Mn V $ 455 mn 🔴🔴
30-Oct-2026 14:21:24
• NET PROFIT AT ₹2,501 CR VS EST ₹3,085 CR — MISS BY 18.93% 🔴 • REVENUE AT ₹16,198.7 CR VS EST ₹15,766.1 CR — BEAT BY 2.74% 🟢 • EBITDA AT ₹4,743.5 CR VS EST…
30-Oct-2026 08:06:42
• US FDA approved supplemental Biologics License Application for ILUMYA (tildrakizumab-asmn) for adults with active psoriatic arthritis (PsA) • IL-23 inhibitor…
23-Oct-2026 18:02:20
• Updated long-term efficacy and safety data from pivotal CK-301-101 trial across three advanced CSCC cohorts, 205 patients • Group 2 (laCSCC) objective respon…
23-Oct-2026 08:26:22
• Fundraising: Raised ₹7,816 Cr through bond issuance against planned ₹10,000 Cr • 5-Year Bonds: Priced at 8.05% annual coupon rate • 7-Year Bonds: Priced at 8…
20-Oct-2026 17:35:00
• NCCN elevated UNLOXCYT (cosibelimab-ipdl) to a Category 2A recommended option for locally advanced cutaneous squamous cell carcinoma (laCSCC) patients who ar…
12-Oct-2026 19:57:55
• Board approved issuance of listed, rated, unsecured, redeemable non-convertible debentures on private placement basis in one or more tranches • Aggregate amo…
07-Oct-2026 20:40:38
Board to consider private placement of listed, rated, unsecured, redeemable non-convertible debentures in one or more tranches, aggregate not exceeding ₹15,000…
06-Oct-2026 18:24:46
• Endowment to fund academic leadership in dermatology in perpetuity, supporting research, education and mentorship. • Mark G. Lebwohl, MD, installed as inaugu…
01-Oct-2026 17:48:46
• LEQSELVI® (deuruxolitinib) will be featured in seven presentations at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. • A featured…
28-Sept-2026 08:21:26
• Sun Pharma inks exclusive licensing agreement with LIB Therapeutics to commercialize and manufacture lerodalcibep worldwide, excluding the US and China. • Ly…
20-Jun-2026 17:24:28
• Sun Pharma to acquire 100% of Innovcare Lifesciences Pvt Ltd. • Innovcare markets pharma, nutraceutical and cosmeceutical products. • Strategic investment to…
14-Jun-2026 12:02:22
• Company has received information regarding the arrest of Mr. Gautam Doshi, Independent Director. • The matter is not connected with the Company. • No impact…